Literature DB >> 18760782

Isolation of human mesenchymal stem cells from third-trimester amniotic fluid.

Qi You1, Liying Cai, Jianhua Zheng, Xiaojing Tong, Dan Zhang, Yuanlong Zhang.   

Abstract

OBJECTIVE: To determine whether mesenchymal stem cells (MSCs) can be isolated in third-trimester amniotic fluid (AF) and their differentiation induced.
METHOD: Sufficient numbers of MSCs were isolated from the AF of 15 healthy women undergoing cesarean delivery in the third trimester to be cultured and induced to differentiate into osteocytes.
RESULTS: Reverse-transcriptase polymerase chain reaction showed the MSCs to express the pluripotency marker gene OCT4, and flow cytometry showed these cells to be positive for CD29, CD73, CD90, and CD105 and negative for CD31, CD45, and CD61. The MSCs were also determined to be nontumorigenic.
CONCLUSION: Multipotent MSCs can be obtained from AF in the third trimester, which may be less dangerous than the second trimester to women and their fetuses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18760782     DOI: 10.1016/j.ijgo.2008.06.012

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  24 in total

1.  Analysis of CD14 expression levels in putative mesenchymal progenitor cells isolated from equine bone marrow.

Authors:  Catherine H Hackett; Maria Julia B F Flaminio; Lisa A Fortier
Journal:  Stem Cells Dev       Date:  2010-10-12       Impact factor: 3.272

Review 2.  Immunomodulatory nature and site specific affinity of mesenchymal stem cells: a hope in cell therapy.

Authors:  Parisa Lotfinegad; Karim Shamsasenjan; Aliakbar Movassaghpour; Jafar Majidi; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2013-12-23

Review 3.  Isolation and in vitro characterization of bovine amniotic fluid derived stem cells at different trimesters of pregnancy.

Authors:  B Rossi; B Merlo; S Colleoni; E Iacono; P L Tazzari; F Ricci; G Lazzari; C Galli
Journal:  Stem Cell Rev Rep       Date:  2014-10       Impact factor: 5.739

4.  Comparison of equine bone marrow-, umbilical cord matrix and amniotic fluid-derived progenitor cells.

Authors:  Arianna Barbara Lovati; Bruna Corradetti; Anna Lange Consiglio; Camilla Recordati; Elisa Bonacina; Davide Bizzaro; Fausto Cremonesi
Journal:  Vet Res Commun       Date:  2010-12-31       Impact factor: 2.459

5.  Temporal analysis of equine bone marrow aspirate during establishment of putative mesenchymal progenitor cell populations.

Authors:  Catherine H Radcliffe; M Julia B F Flaminio; Lisa A Fortier
Journal:  Stem Cells Dev       Date:  2010-02       Impact factor: 3.272

Review 6.  Amniotic fluid-derived stem cells for cardiovascular tissue engineering applications.

Authors:  Jennifer Petsche Connell; Gulden Camci-Unal; Ali Khademhosseini; Jeffrey G Jacot
Journal:  Tissue Eng Part B Rev       Date:  2013-03-14       Impact factor: 6.389

7.  The Production of Pluripotent Stem Cells from Mouse Amniotic Fluid Cells Using a Transposon System.

Authors:  Enrica Bertin; Martina Piccoli; Chiara Franzin; Andras Nagy; Maria Mileikovsky; Paolo De Coppi; Michela Pozzobon
Journal:  J Vis Exp       Date:  2017-02-28       Impact factor: 1.355

8.  Cell phenotypes in human amniotic fluid.

Authors:  D A Davydova; E A Vorotelyak; Yu A Smirnova; R D Zinovieva; Yu A Romanov; N V Kabaeva; V V Terskikh; A V Vasiliev
Journal:  Acta Naturae       Date:  2009-07       Impact factor: 1.845

9.  A novel method to derive amniotic fluid stem cells for therapeutic purposes.

Authors:  Tatsanee Phermthai; Yuparat Odglun; Suphakde Julavijitphong; Vitaya Titapant; Prakong Chuenwattana; Chanchai Vantanasiri; Kovit Pattanapanyasat
Journal:  BMC Cell Biol       Date:  2010-10-19       Impact factor: 4.241

10.  Mesenchymal Stem Cells Stabilize Atherosclerotic Vulnerable Plaque by Anti-Inflammatory Properties.

Authors:  Shuang-shuang Wang; Si-wang Hu; Qing-hua Zhang; Ai-xiang Xia; Zhi-xin Jiang; Xiao-min Chen
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.